No Data
No Data
Climb Bio Fueled Up With Cash, Poised for More Milestones in '25 – Quarterly Update Report
Express News | Climb Bio Inc: Files for Offering of Common Stock up to $22.4 Mln - SEC Filing
Eliem Therapeutics GAAP EPS of -$0.13 Beats by $0.02
Climb Bio Reports Q4 EPS (13c) Vs (13c) Last Year
Express News | Climb Bio Q4 2024 GAAP EPS $(0.13) Beats $(0.15) Estimate
Express News | Climb Bio Inc - Expects Cash Runway Through 2027